Conflict of interest statement: Conflict of Interest Disclosures: Dr. Takeshita 
receives a research grant (to the Trusteees of the University of Pennyslvania) 
from Pfizer and payment for continuing medical education work related to 
psoriasis. Dr. Mehta is a full time U.S. Government employee. Dr. Ogdie receives 
research grants from AbbVie (to the Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis [GRAPPA]), Celgene (to GRAPPA), and Pfizer 
Inc. (to the Trustees of the University of Pennsylvania and GRAPPA), and has 
served as a consultant for Novartis, receiving honoraria. Dr. Van Voorhees has 
served as a consultant for AbbVie, Amgen, Aqua, Astra Zeneca, Celgene, Corrona, 
Dermira, Janssen, Leo, Novartis, and Pfizer, receiving honoraria; received a 
research grant from AbbVie; and has other relationship with Merck. Dr. Gelfand 
has served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli 
Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, 
Endo, and Pfizer Inc., receiving honoraria; and receives research grants (to the 
Trustees of the University of Pennsylvania) from AbbVie, Amgen, Eli Lilly, 
Janssen, Novartis Corp, Regeneron, and Pfizer Inc.; and received payment for 
continuing medical education work related to psoriasis. Dr. Gelfand is a 
co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma.